Back to speakers



City: London

Institution: Kings College Hospital

Biography of Geoffrey DUSHEIKO

Geoffrey Dusheiko, MD, MB, BCh, is an emeritus professor of medicine at the Royal Free Hospital and University College London School of Medicine as well as a consultant hepatologist at King’s College Hospital, London, UK.

He earned his Bachelor of Medicine, Bachelor of Surgery degree from the University of Witwatersrand in Johannesburg, South Africa. After graduating, he completed his internship at Chris Hani Baragwanath Hospital in Johannesburg and his residency at Johannesburg Hospital. His fellowships were conducted at the Johannesburg Hospital Liver Unit, the National Institutes of Health (MD, USA), and the University of Minnesota (MN, USA).

Prof. Dusheiko’s research interests include the management and treatment of HCV, HBV, and small hepatocellular carcinoma. He has a special interest in research on viral hepatitis, particularly viral genotyping, applied molecular virology, the natural history of chronic viral hepatitis, and antiviral therapies. A member of several organisations, including EASL, AASLD, and the International Association for the Study of the Liver (IASL), Prof. Dusheiko is also a fellow of the Royal College of Physicians, the Royal College of Physicians of South Africa, and the Royal College of Physicians of Edinburgh. He served as educational councillor on the Governing Board of EASL for 4 years and was the recipient of the EASL Recognition Award in 2014.

In addition to being on the editorial board of the Journal of Viral Eradication, he is co-editor of Alimentary Pharmacology and Therapeutics and he has previously served on editorial boards for the Journal of Viral Hepatitis, Hepatology, Best Practice & Research: Clinical Gastroenterology, and Gut, among others. Prof. Dusheiko has authored or co-authored more than 400 articles published in international peer-reviewed journals or books. He has served as interim Deputy Director Hepatitis HIV STI and Blood Safety Division Public Health England

PHC's participations

Tuesday, March 28th 2023


Wednesday, March 29th 2023


Wednesday, March 29th 2023


Monday, March 08th 2021

HBV cure: How and when? -

13th PHC – 2020

Monday, January 13th 2020

HEPATITIS B - SESSION 2: therapy of hepatitis B tomorrow: HBV cure (chairman) -

Will we need novel combinations to cure HBV infection? -

12th PHC – 2019

Tuesday, January 15th 2019

HEPATITIS B - SESSION 1 (chairman)

The impact of HBV therapy on public health -

DAY 1 – Friday, August 28

Friday, August 28th 2015

Antiviral treatment in HCV cirrhotic patients on waiting list (chairman) -

Saturday, August 29th 2015

Hepatitis C: new challenges in the era of DAAs (chairman)

1st PHC – 2004

Saturday, September 11th 2004

Treatment of HBeAg-Positive Chronic Hepatitis B with Nucleoside/Nucleotide Analogs (chairman) -

2nd PHC – 2007

Tuesday, January 23rd 2007

Why do I treat my patients with nucleos(t)ide analogues ? -

3rd PHC – 2009

Tuesday, January 20th 2009

HBeAg-positive chronic hepatitis B (chairman)

4th PHC – 2011

Tuesday, January 18th 2011

HBeAg-negative chronic hepatitis B (chairman)

5th PHC – 2012

Monday, January 30th 2012

Triple therapy today. Phase III results in G1 relapsers and non responders (chairman)

6th PHC – 2013

Tuesday, January 15th 2013

Why do I treat my patient with pegylated IFN? -

Interactive Luncheons - Room 4 (chairman)

11th PHC – 2018

Monday, January 15th 2018

Luncheon workshops - (chairman)

10th PHC – 2017

Monday, January 30th 2017

Impact of therapy on the QOL

LUNCH WORKSHOPS - 3-DAAs treatment of patient with HIV-HCV co-infection -